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Objective: To evaluate the efﬁ  cacy of Systane® Lubricating Eye Drops in improving the 
symptoms of moderate ocular dryness.
Methods: Fifty subjects with moderate symptoms of ocular dryness were enrolled in this 
open label study. The mean age of subjects was 57.6 ± 15.4 years. To be eligible, subjects’ 
tear ﬁ  lm break-up time (TFBUT) had to be  10 seconds, and subjects had to have at least one 
ocular discomfort symptom in addition to dryness. Saline was used for a wash-out period of 
3–5 days. Subjects were re-examined, and those continuing to meet the inclusion criteria were 
dispensed Systane® and re-examined again after 28 days. At each visit, slitlamp examination 
was conducted, and ocular discomfort symptoms and TFBUT were evaluated. Subjects rated 
their overall satisfaction at baseline and on the last visit.
Results: No signiﬁ  cant changes in TFBUT or ocular discomfort symptoms were observed after 
saline use, compared with screening visit. After 28 days of Systane® use there was statistically 
signiﬁ  cant improvement of TFBUT (p = 0.0001) compared with baseline. Subjects experienced 
signiﬁ  cant symptomatic relief for all 6 ocular discomfort symptoms at the endpoint visit.
Conclusion: Systane® effectively relieved the symptoms associated with moderate ocular 
dryness, with measurable improvement in objective TFBUT, subjective symptoms, and overall 
satisfaction.
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Introduction
The tear ﬁ  lm contains a mixture of lipid, aqueous, and mucin layers. It is generally 
accepted that the tear ﬁ  lm in subjects with ocular dryness is unstable and incapable of 
maintaining the protective qualities that are necessary for its structure and function.
When the tear ﬁ  lm is compromised, the corneal and conjunctival epithelium cannot 
be maintained, and subjects experience the symptoms of discomfort associated with 
ocular dryness such as burning, stinging, grittiness, foreign body sensation, tearing, 
ocular fatigue, and dryness (Terry 2001). The mainstay therapy of ocular dryness is 
tear ﬁ  lm correction and improvement with topically administered lubricant eye drops 
substitutes, which provide mostly a transient relief due to low retention time on the 
eye surface.
Systane® Lubricating Eye Drops (Alcon Laboratories, Inc., Fort Worth, Texas, USA) 
contain polyethylene glycol 400 (0.4%) and propylene glycol (0.3%) demulcents with 
the polymer hydroxypropyl guar (HP-Guar) as a gelling agent, and are preserved with 
POLYQUAD® (polidronium chloride) 0.001%. In the bottle, Systane® consists of a 
loosely cross-linked meshwork created by covalent interactions between borate and HP-
Guar. When exposed to the higher pH of the ocular surface and tears, which is approxi-
mately 7.5 (Yamada et al 1997), HP-Guar forms a reversible cross-link with borate, Clinical Ophthalmology 2008:2(3) 630
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resulting in a gel-matrix with sheer thinning viscoelastic and 
bioadhesive properties (Figure 1). The gel-matrix is designed 
to promote retention of the active demulcents, and, thus, 
protects the ocular surface (Asgharian et al 2003; Hartstein 
et al 2005; Gifford et al 2006; Meyer 2006).
The purpose of this study was to examine the clinical 
efﬁ  cacy of Systane® Lubricating Eye Drops in reducing the 
subjective symptoms of moderate ocular dryness in a speciﬁ  c 
patient population.
Methods
Study population
Fifty healthy adults, regardless of gender or race, were 
enrolled at one research site in Bologna, Italy. The study 
was approved by an Independent Ethics Committee and was 
conducted in accordance with the current ethical principals of 
the Declaration of Helsinki and in accordance with the current 
legislation on clinical research in Italy. All subjects signed an 
informed consent form before starting the study. The inclu-
sion/exclusion criteria were designed to exclude subjects with 
mild symptoms of ocular dryness, and to include subjects with 
moderate symptoms of ocular dryness (Table 1).
Materials
Sterile saline (0.9% NaCl, Mini-Plasco. B. Braun, Meisungen, 
Germany) for the wash-out period. Systane® Lubricating Eye 
Drops as the test article.
Study design
This was a prospective, open-label, single-center study. The 
study consisted of 3 ofﬁ  ce visits carried out in an approximately 
5-week period – visit 1 (screening), visit 2 (Day 0/baseline, 
3–5 days after visit 1), and visit 3 (Day 28/endpoint, 28 days 
after visit 2). Each visit was conducted at approximately 
the same time of day (in the afternoon). Subjects’ tear ﬁ  lm 
break-up time (TFBUT) had to be  10 seconds, and subjects 
had to have at least 1 ocular discomfort symptom in addition 
to dryness to be eligible. Saline was used for a run-in period 
of 3–5 days. At the screening visit, subjects’ demographic 
information was recorded, along with current/prior use of 
medications, lubricant eye drops, and ocular pathologies 
(Table 2). Medications considered necessary to maintaining 
subjects’ health were used at the discretion of the investigator. 
Subjects were questioned on how often their eyes felt dry 
enough for them to want to use lubricant eye drops (none, 
some, half, most, or all of the time). Furthermore, subjects 
were asked to complete an “Ocular Discomfort – Severity 
Questionnaire” grading the severity of their ocular sensations 
(burning, stinging, grittiness, dryness, foreign body sensation, 
and itching) on a 4-point scale (Grade: 0 = no discomfort; 
1 = mild discomfort; 2 = moderate discomfort; 3 = serious 
discomfort).
A thorough slit-lamp biomicroscope examination was 
conducted to examine and record any abnormalities in the 
lids/eyelashes, anterior chamber, iris, and lens, as well as 
Figure 1 Chemical composition and mechanism of action of Systane® Lubricating Eye Drops.
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to grade the level of conjunctival injections (Grade: 0 = 
none – normal, no hyperemia; 1 = mild, trace hyperemia; 2 = 
moderate, diffuse hyperemia; 3 = severe, horizontal banding 
of hyperemia). TFBUT, which is deﬁ  ned as the time taken 
from blink until the ﬁ  rst dark spots or streaks appear within 
the ﬂ  uorescein enhanced tear ﬁ  lm (Barabino et al 2004), was 
measured and recorded (average of 3 measurements) using 
sodium ﬂ  uorescein strips (Haag-Streit International). Subjects 
who met the inclusion criteria of the study were dispensed 
saline solution as a run-in drop. This served to normalize the 
study population to an identical regimen of eye drops use, 
and allowed for washout and minimization of any effect from 
previous lubricant eye drops/medications use. Subjects were 
instructed to use the saline drops 4 times daily (qid) in both 
eyes. In addition, subjects were instructed to administer the 
saline eye drops at 8:00 AM on the day of their next ofﬁ  ce 
visit (Day 0/baseline) and to refrain from administering any 
other eye drops until after the examination. This allowed for 
approximately 6 hours between the last administration of eye 
drops and TFBUT measurements.
After 3–5 days, subjects returned (visit 2: Day 0/baseline) 
for an eligibility follow-up examination in which the above 
measurements were repeated. In addition, subjects answered 
a satisfaction questionnaire. Subjects continuing to satisfy 
the inclusion criteria were dispensed Systane® Lubricating 
Eye Drops and were instructed to use 1–2 drops in each 
eye qid (upon awakening, noon, early evening, and before 
bedtime). Likewise, subjects were instructed to administer 
Systane® drops at 8:00 AM on the day of their next ofﬁ  ce 
visit (Day 28/endpoint) and to refrain from administering 
any other eye drops until after the examination. After 28 
days (visit 3: Day 28/endpoint), subjects returned for fol-
low-up. The same examination measures and questions of 
visits 1 and 2 were repeated. In addition, subjects were asked 
to complete a satisfaction questionnaire. The satisfaction 
questionnaire included the following statements: “my eyes 
feel dry in the morning,” “my eyes feel dry at the end of the 
day,” “my eyes feel comfortable upon instillation of drops,” 
“my eyes feel refreshed when I use the drops,” “my eyes 
feel refreshed longer than expected when I use the drops,” 
and “I frequently forget my symptoms during the use of the 
drops.” Subjects recorded their answers using a 5-point scale 
(Scale: 1 = strongly disagree, 2 = disagree, 3 = undecided, 
4 = agree, and 5 = strongly agree). Adverse events were also 
reported on visit 3.
Statistical analysis
The usual descriptive statistics were performed for all 
variables: average, standard deviation (SD), mean, minimum/
maximum value for continuous variables, and absolute/
relative frequency of categorical variables. Also, a t test was 
used with a bilateral signiﬁ  cance level of 5%.
Results
Fifty subjects were enrolled and successfully completed 
all aspects of the study. The mean age of subjects was 
57.6 ± 15.4 years (range, 26–85); 40 subjects were female. 
When asked how often their eyes felt dry enough to want 
to use lubricant eye drops, none of the subjects responded 
with “none of the time,” 30 subjects responded “some,” 
17 “half,” 2 “most,” and 1 subject responded “all of the 
time.” When questioned regarding their current use of 
lubricating eye drops, 44 subjects reported use of lubricat-
ing eye drops.
Tear ﬁ  lm break-up time
The tear ﬁ  lm analysis showed no signiﬁ  cant changes in 
TFBUT between screening and baseline visit (6.8 seconds 
OD and 6.9 seconds OS). However, a statistically signiﬁ  -
cant increase was observed in the mean sodium ﬂ  uorescein 
TFBUT from 6.9 seconds at baseline visit to 8.5 seconds at the 
endpoint visit (Day 28) in the left eye, and from 6.8 seconds 
to 8.5 seconds in the right eye (p = 0.0001) (Figure 2).
Table 1 Inclusion and exclusion criteria
Condition Criteria
Inclusion   •   Subjects who answer “some of the time”, “half 
criteria     of the time”, “most of the time”,  or “all of the time”
    to the question “how often have your eyes felt 
    dry enough to want to use eye drops?”
  •  Subjects who, in addition to complaining of ocular
    dryness sensation, exhibit at least one of the following
    symptoms of ocular discomfort: burning, stinging,
    grittiness, foreign body sensation, or ocular irritation
  •  Subjects with a tear ﬁ  lm break-up time (TFBUT) 
     10 seconds
  •  Subjects who will possibly comply with the study 
   procedures
Exclusion   •  Subjects who answer “none of the time” to the question 
criteria     “how often have your eyes felt dry enough to want to 
use eye drops?”
  •  Subjects with a tear ﬁ  lm break-up time (TFBUT) 
     10 seconds
  •  Subjects who have had refractive eye surgery 
    in the last 6 months
  •   Subjects that use concurrent ocular treatment, not
including lubricant eye drops or lubricants
  •  Subjects known to be allergic to any of the components
   of  Systane
  •  Simultaneous participation in other medical studiesClinical Ophthalmology 2008:2(3) 632
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Ocular discomfort symptoms
No significant changes in ocular discomfort symptoms 
were observed between screening and baseline visits. A 
significant improvement was recorded over the 28-day 
period of the trial for all reported sensations from the 
Ocular Discomfort – Severity questionnaire (Figure 3). 
Burning sensation was reported as “moderate” by 13/50 and 
“serious” by 1/50 subjects at baseline visit. At the endpoint 
visit, burning sensation was reported as “moderate” by 
4/50 and “serious” by 0/50 subjects. Stinging sensation was 
reported as “moderate” by 7/50 subjects at baseline visit 
and by 3/50 subjects at the endpoint visit. These data attest 
to the ability of Systane® to improve the subjective ocular 
discomfort symptoms of ocular dryness.
Overall subjects’ satisfaction
A signiﬁ  cant difference was observed with the overall satis-
faction questions at endpoint visit. Compared with baseline 
visit, most subjects agreed with the statements “My eyes 
feel refreshed when I use the drops” (44/50), “My eyes feel 
comfortable upon instillation of the drops” (36/50), and 
“My eyes feel refreshed longer than expected when I use the 
drops” (21/50). Most subjects responded with “undecided” 
to the statements “My eyes feel dry at the end of the day” 
(27/50), “I frequently forget my symptoms during the use of 
the drops” (27/50), and “My eyes feel dry in the morning” 
(21/50) (Figure 4).
Discussion
Ocular dryness arises from inadequate lubrication of the 
ocular surface from a variety of underlying conditions and 
environmental factors. Though there are many contributing 
factors, ocular dryness is due predominantly to either aqueous 
deﬁ  ciency or excessive evaporation of the tear ﬁ  lm. Although 
new therapeutic strategies based on the pathophysiology of 
ocular dryness are currently being developed, lubricating 
eye drops continue to be the mainstay care of ocular dryness. 
The major goal of these products is to restore ocular surface 
Table 2 Percentage of subjects’ current/prior medications, 
lubricating eye drops, and ocular pathologies at screening visit
  Medication or ocular   Number
 pathology  of  subjects
   (%)
Ocular  Hyaluronic acid  16 (32)
treatments  Eye drops/Hyalistil  7 (14)
 Gental  4  (8)
 Benzalkonium  chloride/Celluvisc  3  (6)
 Carbomer/Cellufresh/Hyaluronate/  2  (4)
 Siccaﬂ  uid/sodium chloride 
 Hylocomod/Lacrinorm/  1  (2)
 Retinol/Systane/Tetramil 
Ongoing ocular  Cataract  2 (4)
pathology Pinguecola  1  (2)
 Pseudophakia  1  (2)
 Strabismus  1  (2)
Prior ocular  Cataract surgery  1 (2)
pathology Pseudophakia  1  (2)
  Retinal detachment  1 (2)
Figure 2 Average increase in tear ﬁ  lm break-up time (TFBUT) from baseline (Day 0) to endpoint visit (Day 28). *p = 0.0001.
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integrity in an attempt to reduce the symptoms associated 
with ocular dryness. Systane® Lubricating Eye Drops provide 
a physical protective barrier that works in conjunction with 
blinking to help spread the tear ﬁ  lm over the eye surface. A 
protected ocular surface, in fact, will exist as long as the tear 
ﬁ  lm is stable and when the TFBUT matches or exceeds the 
inter-blink interval (IBI). Conversely, when the TFBUT is 
less than the IBI, the corneal surface will be unprotected for 
a period of time between blinks, leading to ocular dryness 
(Ousler et al 2007).
Systane® works by binding to the hydrophobic exposed 
areas of the epithelial cells, attaching a protective HP-Guar 
tear-gel matrix that helps restore the ocular surface and 
increase TFBUT (Korb et al 2002, 2005). Ubels et al (2004) 
Figure 3 Percent improvement of patients with ocular discomfort symptoms.
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Figure 4 Subjects’ satisfaction with the improvement of their subjective symptoms at endpoint visit (Day 28) compared with baseline visit (Day 0).
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demonstrated that Systane® provided long-term protection 
from desiccation of the intact cornea. In Ubels’ study, 
Systane® allowed the in vivo exposed corneal epithelium to 
recover the normal barrier function.
The purpose of this current study was to obtain further 
evidence of the clinical efﬁ  cacy of Systane® in reducing 
ocular discomfort symptoms of ocular dryness by increasing 
TFBUT. This study has demonstrated that the use of Systane® 
qid over a 28-day period statistically signiﬁ  cantly extended 
TFBUT. Other studies have investigated the ocular surface 
retention properties of Systane® and its effects on corneal 
and conjunctival staining as well as TFBUT. Gifford et al 
conducted a similar study and showed signiﬁ  cant improve-
ment in ocular symptoms and TFBUT (Gifford et al 2006). 
The authors reported that the gelling properties of HP-Guar 
might be responsible for the stability of the ocular surface 
through its retention of the demulcents on the ocular surface. 
Systane® signiﬁ  cantly increased TFBUT up to 30 minutes 
post instillation compared with carboxymethylcellulose 0.5% 
and polysorbate 80/glycerin (Refresh Tears® and Refresh 
Endura™, Allergan, Inc., Irvine CA, USA), presumably due 
to the HP-Guar borate gel-matrix component (Ousler et al 
2007). Guillon et al demonstrated that Systane® signiﬁ  cantly 
increased TFBUT at each measurement (30 minutes interval) 
up to 120 minutes post instillation (Guillon et al 2004). The 
ocular protection index (OPI) is a measure of the ratio of 
TFBUT to the IBI. D’Arienzo et al demonstrated that Sys-
tane® exhibited a greater extension in TFBUT from baseline 
at 45, 60, and 90 minutes postdrop instillation than Optive™ 
during the important sustaining phase, indicating its ability 
to lubricate and protect the ocular surface for a longer period 
than Optive. However, both Systane® and Optive™ showed 
improvements shortly after instillation during the bulking 
phase (D’Arienzo et al 2007).
The overall results from the Ocular Discomfort – Severity 
questionnaire showed that the use of Systane® during the 
course of this study was associated with a signiﬁ  cant reduction 
of ocular discomfort. Two similar studies conducted by Gifford 
et al (2006) and Harstein et al (2005) asking the same questions 
over the same duration and using an identical Systane® regimen 
also showed signiﬁ  cant overall reduction of ocular discomfort. 
Therefore, this current study adds more evidence and weight 
to the conclusions drawn by Gifford and Hartstein, which state 
that Systane® is effective in improving ocular discomfort in 
subjects with moderate symptoms of ocular dryness, one of 
the primary roles of lubricating eye drops.
The ﬁ  nal part of this study examined the subjects’ overall 
satisfaction with Systane® as lubricant eye drops by looking 
into subjects’ responses to 6 acceptability elements at the 
endpoint visit. Gifford et al (2006), Hartstein et al (2005), and 
Christensen et al (2004) reported the use of similar questions 
and the receipt of similar responses in their corresponding 
clinical studies. Subjects were aware of the relief Systane® pro-
vided, agreeing more strongly to “My eyes feel refreshed when 
I use the drops.” The frequency of symptoms was also reduced, 
with most subjects agreeing, “My eyes feel refreshed longer 
than I expected.” Some subjects could not answer some of the 
acceptability questions and reported “uncertain/undecided” as 
their answer. One possible reason may be the ambiguity of the 
statements themselves, leaving the patient undecided.
Limitations of this study are that it was an open-label 
and uncontrolled study that did not control for the placebo 
effects or compare the results with that of a control group, 
although the symptoms at the endpoint visit were compared 
with the symptoms at the baseline visit. Therefore, a future 
double-masked, randomized, controlled study design with 
perhaps longer duration to study the long-term effects of 
Systane® on ocular dryness is warranted.
Conclusion
Systane® Lubricating Eye Drops improved the symptoms 
of ocular discomfort in subjects with moderate symptoms 
of ocular dryness. Statistically signiﬁ  cant improvement was 
evident in the extension of TFBUT from Day 0/baseline to 
Day 28/endpoint. Subjective symptoms also showed signiﬁ  -
cant improvement and overall, subjects were satisﬁ  ed with 
the use of Systane®.
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